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Immunotherapy aims to assist the natural immune system in achieving control over viral infection. Various
immunotherapy formats have been evaluated in either therapy-naive or therapy-experienced HIV-infected patients
over the last 20 years. These formats included non-antigen specific strategies such as cytokines that stimulate
immunity or suppress the viral replication, as well as antibodies that block negative regulatory pathways. A number
of HIV-specific therapeutic vaccinations have also been proposed, using in vivo injection of inactivated virus,
plasmid DNA encoding HIV antigens, or recombinant viral vectors containing HIV genes. A specific format of
therapeutic vaccines consists of ex vivo loading of autologous dendritic cells with one of the above mentioned
antigenic formats or mRNA encoding HIV antigens.
This review provides an extensive overview of the background and rationale of these different therapeutic attempts
and discusses the results of trials in the SIV macaque model and in patients. To date success has been limited,
which could be explained by insufficient quality or strength of the induced immune responses, incomplete
coverage of HIV variability and/or inappropriate immune activation, with ensuing increased susceptibility of target
cells.
Future attempts at therapeutic vaccination should ideally be performed under the protection of highly active
antiretroviral drugs in patients with a recovered immune system. Risks for immune escape should be limited by a
better coverage of the HIV variability, using either conserved or mosaic sequences. Appropriate molecular adjuvants
should be included to enhance the quality and strength of the responses, without inducing inappropriate immune
activation. Finally, to achieve a long-lasting effect on viral control (i.e. a “functional cure”) it is likely that these
immune interventions should be combined with anti-latency drugs and/or gene therapy.
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Introduction: functional cure and natural immune control
of HIV
During last year’s International AIDS Society (IAS) Con-
ference (July 2011) the “Rome Statement for an HIV
Cure” was issued, pleading for “the development of a
functional cure which, without completely eliminating
the virus from the body, would permanently suppress its
replication and considerably diminish viral reservoirs,* Correspondence: gvanham@itg.be
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distribution, and reproduction in any mediumpossibly leading to the long-term remission of patients,
in the absence of antiretroviral drugs” (see http://www.
iasociety.org/Default.aspx?pageId=584). More recently
(July 2012), the dedicated IAS Working Group organized
a well-attended symposium in Washington “Towards an
HIV Cure”, accompanied by a “Perspective” paper in Na-
ture Reviews Immunology. Two possibilities for cure
were distinguished: “first, the elimination of all HIV-
infected cells (a sterilizing cure); and second, the gener-
ation of effective host immunity to HIV that would re-
sult in lifelong control of the virus in the absence of
therapy, despite not achieving the complete eradication
of HIV (a functional cure)” [1]. The prototypical ex-
ample of an HIV cure is the well-known “Berlin patient”,ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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radiation in the context of acute myeloid leukemia treat-
ment, was transplanted with hematopoietic stem cells
(HSC) from a homozygous CCR5 delta32 donor and
subsequently remained virus-free without any antiretro-
viral treatment for over 5 years at the time of writing
[2]. Nevertheless, during the recent symposium, data
were presented on some remaining detectable HIV DNA
in rectal biopsies, despite having plasma RNA levels
below 1 copy and a complete absence of viral DNA,
RNA or cultivable virus from peripheral blood mono-
nuclear cells (PBMC). Hence, this much-acclaimed pa-
tient is probably an example of a “functional” rather
than of a “sterilizing” cure (S Palmer personal communi-
cation). As a consequence of this unique success story,
several research groups are now attempting to knock
out the CCR5 genes in various cell types, including HSC
[3]. Results of syngeneic CCR5(−) HSC transfer in
humanized mice indicate that, upon infection, HIV-1
viral levels are clearly lower, but not absent [4]. Since
it remains uncertain whether this cumbersome gen-
etic therapy will offer a cure for all patients [5],
other strategies need to be considered, including im-
munotherapy and anti-latency drugs, as proposed by
the Working Group (http://www.iasociety.org/Default.
aspx?pageId=606).
Role of HIV-specific immunity in viral control
Several excellent reviews on immune mechanisms of
HIV control have recently been published [6-8]. In the
earliest phase of infection innate responses, including
type-1 interferon (IFN-α/β) and Natural Killer (NK) cells
partly control virus replication. Only after a few weeks
do HIV-specific CD4 and CD8 T cell responses as well
as antibody responses emerge and reduce viral load (VL)
to a patient-specific setpoint [9]. For a long time,
interleukin-12 (IL-12) has been thought to have an es-
sential immune-regulatory role in the induction of a
“Th1-skewed cellular response”, characterized by an op-
timal interplay between IL-2/IFN-γ producing CD4
helper and CD8 effector T cells, which is crucial for the
adaptive phase on anti-viral responses [10].
Examples of the “naturally occurring” functional cure
in HIV infection include the so-called “elite controller”
(EC) HIV-1 patients, who are therapy-naïve but never-
theless keep their “viral setpoint” below 50 RNA copies
per ml plasma [11]. In addition, rare non-controllers ac-
quire a “secondary” controller status after prolonged
“Highly Activate Antiretroviral Therapy” (HAART),
initiated either in the acute phase [12,13] or, even more
rarely, in the chronic phase [14,15].Clearly, this uncom-
mon phenomenon of “post treatment control” (PTC) is
seemingly more easily induced if HAART is started in
the acute as opposed to the chronic phase, pointing to acontribution of a less damaged immune system and/or a
lower proviral reservoir.
Whereas the in-depth study of PTC is just beginning,
more data are available on EC. Decreased viral replica-
tion capacity and genetic host factors have been identi-
fied in a percentage of EC. Unfortunately, these factors
are largely impossible to operationalize with the present
state-of-the art technology. However, an association has
been found between viral control and HIV Gag-specific
CD4 and CD8 T cell responses, but not Env-specific T
cells or Env-specific neutralizing antibodies, pointing to
an important role for HIV-specific T cell immunity to-
wards more conserved structural parts of the virus such
as Gag [16,17].
Effective CD8 T cells, capable of keeping the plasma
viral load under control, are characterized by a central
and effector-memory phenotype, low levels of aberrant
activation and exhaustion markers (e.g. CD38 and pro-
grammed death (PD)-1), and preserved costimulatory
receptors (e.g. CD28). Effective HIV-specific CD8 T cells
produce multiple cytokines and effector molecules; they
have preserved proliferative capacity; and their T cell
receptors show high avidity and/or cross-reactivity, pre-
ferentially recognizing conserved epitopes in Gag, thus
leaving little opportunity for immune escape [16,17]. Im-
portantly, these CD8 T cells also show a high-avidity
cytolytic potential against infected cells [18] and have
the capacity to suppress viral replication in vitro [19,20].
These observations provide a rationale to attempt to de-
velop strategies to enhance immune control by “thera-
peutic vaccination” [11,21].
In order to induce and maintain this type of effective
CD8 T cells, a well-coordinated interaction with den-
dritic cells (DC) and CD4 T cells is important [22]. HIV-
specific CD4 T cells play an important role by producing
“helper” cytokines, such as those triggering the “com-
mon γ chain receptors” (IL-2, IL-7 and IL-21), as well as
by upregulating costimulatory membrane markers such
as CD40L as well as CD80 and CD86, which promote
CD8 T cell survival, proliferation, cytotoxicity and virus-
suppressive capacity [6,23]. DC can directly activate
CD8 T cells, but also induce effective CD4 T cell help to
CD8 T cells. Therefore, harnessing the DC function to
improve the quality of T cell responses against HIV can
be an important mechanism in immunotherapy [24,25].
The danger of an activated immune system
Progressive HIV infection is characterized by persistently
increased levels of various soluble inflammatory mar-
kers, dysregulation of T cell surface markers, and upre-
gulation of receptors for immune suppressor signals
such as PD-1 and cytolytic T-lymphocyte antigen
(CTLA)-4. This inappropriate immune activation is
partly due to a persistent VL, but in addition endotoxins
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“leaky gut” and “hypersensitivity” to type 1 IFN have
been implicated (for review see [26]). A sizeable body of
evidence suggests that this persistent “immune activa-
tion syndrome” constitutes a bad prognostic sign, inde-
pendent from CD4 T cell count, plasma VL and cellular
proviral load, even under suppressive HAART [27]. Un-
surprisingly, inappropriate T cell activation is associated
with increased susceptibility of CD4 T cells to infection
and decreased T cell responsiveness to antigenic stimula-
tion, including reduced IL-2 production, and increased
apoptosis. This activation-induced “T cell exhaustion”
conceptually limits the possibilities of immunotherapy
and therefore it is important to provide sufficient co-
stimulatory signals [28], without increasing susceptibility
of target cells to HIV.
The role of HAART and viral reservoirs
HAART reduces VL and immune activation, and there-
fore it was hoped that long-term HAART would allow
the immune system to recover its capacity to control the
virus. A number of “structured treatment interruption”
(STI) trials have indicated that while immune responses
to HIV were boosted, the VL rebounded to pre-
treatment levels in most patients (except for the rare
“secondary controllers” or PTC), suggesting that infec-
tious virus is not a good antigen for immune therapy
[29]. The fundamental problem to fully eradicate the
virus is the persistence of a “latent” reservoir. Neither
long-term treatment with classical HAART cocktails
(based on reverse transcriptase and protease inhibitors)
nor treatment intensification with newer integrase or
entry-inhibitors can consistently reduce this reservoir
(for review see [30]).
One proposed strategy for cure is to activate the la-
tent provirus under coverage of HAART: the rescued
virus will kill the producer cell, but cannot infect new
targets . Many excellent reviews have been dedicated
to this complicated challenge [3,31,32]. The y-chain
cytokine interleukin-7 (discussed below for its immune
stimulating potential) is currently under study for its
potential to “purge” the latent HIV reservoir (ERA-
MUNE trial, http://www.clinicaltrials.gov). A number
of pharmacological agents, including (combinations of )
histone-deacytelase inhibitors, NF-κβ activating agents
and others have shown some HIV-rescuing activity
in vitro. This has been accompanied, however, by glo-
bal T cell activation and, until now, no convincing fa-
vorable clinical data have been reported [30]. Many
pharmaceutical companies are currently screening
compound libraries to find novel factors that could
more potently and more selectively rescue the latent
virus, but this topic is beyond the scope of the present
review.In the context of immunotherapy, however, anti-
latency drugs are relevant; even if they were unable to
“purge” the reservoir by themselves. In fact, complete la-
tency renders infected cells invisible to the immune sys-
tem, precluding targeting by therapeutic vaccination.
Anti-latency drugs could overcome this hurdle, because
they induce expression of viral proteins that would mark
the infected cells as targets for immune elimination
[33,34].
In conclusion, several principles can be proposed for
immunotherapy. These include a non-specific enhance-
ment of anti-viral immune responses by various immune
stimulators, including type-1 IFN, IL-12 and the so-
called common γ-chain signaling cytokines, related to
IL-2. In addition, blocking antibodies against immune
suppressive receptors such as PD-1 and CTLA-4 could
also provide beneficial immune stimulation. On the
other hand, a range of antigenic formats have been pro-
posed to induce HIV-specific T cell responses, in order
to elicit more effective CD8 T cell-mediated immune
surveillance.
In the following paragraphs, we will explain the ration-
ale of each strategy and then focus mainly on thera-
peutic vaccination trials in Simian Immunodeficiency
Virus (SIV)-infected macaques and HIV infected
patients, critically investigating their potential to com-
plement (and ultimately replace) anti-retroviral drug
therapy. Clearly, no definite strategy for a cure has been
established yet, but encouraging results are emerging
and the concepts are slowly but surely maturing.
Non-antigen specific immune therapies
An overview is presented in Table 1.
Cytokine therapies
Type-1 interferon During the acute phase of HIV infec-
tion, high levels of serum IFN-α are part of the innate
antiviral response, as in vitro results showed that IFN-α
indeed reduced HIV replication in both CD4 T cells and
monocytes-macrophages. However, the role of type-1
IFN in HIV pathogenesis is rather ambiguous, since in
the chronic phase, serum markers of increased IFN ac-
tivity, such as neopterin and β2-microglobulin have con-
sistently been associated with a bad prognosis [49].
Based on the first premise (type 1 interferon = anti-
viral), in vivo IFN-α treatment was attempted in the era
before anti-retroviral drugs were available, but failed to
provide benefit in Acquired Immune Deficiency Syn-
drome (AIDS) patients; whereas in infected patients with
preserved immunity a trend to a better clinical outcome
was noted. Later, IFN-α was combined with monother-
apy or bi-therapy of nucleoside reverse transcriptase
inhibitors (NRTI). A trend for increased antiviral effects
Table 1 Non antigen-specific immune therapy











Human HAART IL-12 sc, single dose 47 Dose related increase in serum IFN-γ




Human HAART IL-12 sc, multi dose twice weekly
for 4 weeks.
56 Well tolerated at doses up to 100 ng/kg.
Dose related increase in neopterin levels.
No differences in other immunological




Human Mono- or dual treated IL-2 iv intermittent 5 days regimen 155 Higher CD4 T cell count, lower VL
and 43% reduction in risk of disease
progression or death.
[37]
SILCAAT Human HAART Low CD4 T
cell count
IL-2 sc 6 cycles of IL-2 twice
daily for 5 consecutive days
1695 Sustained effect on CD4 T cells without
affecting clinical progression
[38]
ESPRIT Human HAART High CD4 T
cell count
IL-2 sc 3 cycles of IL-2 twice
daily for 5 consecutive days






Human Therapy naïve IL-2 sc 3 cycles of IL2 for 5
consecutive days
130 Sustained increase in CD4 T cells without
affecting viral load.
[39]
ANRS-NIH ILIADE Human HAART with high CD4 IL-2 sc 3 cycles of IL2 for 5
consecutive days. ATI on
week 24
148 Delay HAART resumption following





Human Therapy naïve IL-7 sc, single injection 25 Increased numbers of circulating CD4 and




Human HAART IL-7 sc repeated injections. Eight
doses 3 times a week
13 Expansion of naïve CD4 and CD8 T cells. [42]
Rhesus
macaque
Chronic SIV IL-7 sc 4 injections every 3 weeks 9 Counteracts IFN-α induced lymphopenia.




Chronic SIV +HAART IL-15 sc twice a week from day 0-day42 16 Delayed viral suppression. Failed to enhance
antigen-specific CD4 T cell reconstitution at
mucosal and lymphoid sites. Upon ATI loss of




Chronic SIV IL-21 2 iv injections 7 days apart
and 3 sc doses 23 days
after 2nd vaccination.
7 Safe and well tolerated. Increased cytotoxic





Chronic SIV Blocking Ab to PD-1 Iv 14 Expansion virus specific CD8 T cells and





Chronic SIV +HAART Blocking Ab to CTLA4 iv 16 Increase CD4 and CD8 T cell responses




Chronic SIV +HAART Blocking Ab to CTLA4 iv 10 No expansion SIV specific T-cells. Increased
activation of T cells and increased viral
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flu-like side effects [50]. Once efficient HAART tri-
therapy became available, combinations with type 1
interferons were abandoned for the indication of HIV in-
fection alone (though they are still in use for selected
cases of chronic hepatitis and HIV co-infection).
Since elevated IFN-α levels are suspected to play a role
in pathological immune activation, Zagury et al.
attempted to immunize HIV patients against this cyto-
kine. The subgroup of patients with a rise in anti-IFN-α
antibodies had a significantly lower incidence of HIV-1-
related events compared with placebo recipients and
vaccinees who failed to develop antibodies [51].
A different approach was used more recently with the
anti-malarial drug chloroquine. Preliminary evidence
in vitro and in vivo indicated that chloroquine reduces
IFN-α production and decreases the level of immune ac-
tivation [52]. A randomized double blind placebo-
controlled trial in therapy-naïve patients, however, failed
to show any favorable effect on immune activation and,
unfortunately, did result in a greater decline in CD4 T
cell count and increased VL [53].
Interleukin-12 A Th1/Th2 imbalance has traditionally
been regarded as a hallmark of HIV-related immune
dysfunction [54]. IL-12 represents the archetypical Th1
switching agent: it induces type II interferon (IFN-γ)
production by T cells and NK cells and increases their
cytotoxic capacity against virally infected cells [10]. A
number of in vitro studies in PBMC cultures from HIV
infected subjects confirmed that IL-12 increased Th1
responses [55,56]. Before the HAART era, two phase 1
studies of subcutaneous (sc) IL-12 were conducted in
medically stable HIV-infected patients. Single doses of sc
IL-12 between 30 and 300 ng/kg were reasonably toler-
ated and induced a dose-related increase of serum IFN-
γ, but failed to influence CD4 T counts or VL [35]. In a
subsequent placebo-controlled multi-dose trial, IL-12
was tolerated in doses up to 100 ng/kg, but again no ef-
fect on CD4 T counts or VL was observed [36]. Appar-
ently, repeated IL-12 administration resulted in
“tolerance”, and overdosing could even result in para-
doxical immune suppression through activation of NO
production [57,58]. Nowadays, in many experimental
immunization schedules with HIV antigens in either
plasmid DNA or viral vectors, an expression cassette for
IL-12 is being added, thus focusing IL-12 expression at
the site of immunization and avoiding systemic side
effects.
Common γ chain signaling cytokines These cytokines
include IL-2, -4, -7, -9, -13, -15 and -21 and bind to re-
ceptor complexes that include the so called common γ
signaling chain. Among these, IL-4, -9 and -13 skew theimmune system towards Th2 responses, considered
pathogenic in HIV infection. The other γ chain cyto-
kines have potentially beneficial effects to overcome im-
mune dysfunction [59,60].
IL-2 enhances both CD4 T cell proliferative and CD8
T cytolytic functions, but may also induce peripheral tol-
erance by activating regulatory T cells (Treg) [61]. Defi-
cient IL-2 production upon antigenic stimulation has
consistently been reported as a hallmark of HIV-related
immune dysfunction, from the early 80’s on [62,63].
Interleukin-7 has been shown to play a crucial role in
promoting expansion and maintenance of T cells. IL-7
production is increased during HIV-induced lymphope-
nia, but this feedback is apparently not sufficient to
maintain T cell homeostasis [64]. The primary role of
IL-15 is to expand the effector-memory subset of CD8 T
cells, which is crucial in immune control, and to pro-
mote survival of NK cells. Several studies have shown
that IL-15 production is compromised in AIDS patients,
and supplementation of IL-15 improves the function of
immune cells from these patients in vitro [65]. Finally,
IL-21 promotes proliferation and accumulation of
antigen-specific CD8 effector T cells, increases their sur-
vival and cytolytic potential, especially in synergy with
other cytokines, and promotes differentiation of naive
CD4 T cells without inducing Treg. IL-21 production is
compromised early on during HIV infection and it is
only partly restored by HAART [66].
Therapeutic use of interleukin-2 A number of smaller
studies in the 90’s evaluated systemic IL-2 therapy in
HIV patients treated with mono- or dual- NRTI drug
therapy. A pooled analysis suggested that this type of
immunotherapy resulted in higher CD4 T counts, lower
VL, as well as fewer opportunistic infections and deaths
[37]. In order to confirm the observed effects in fully
treated patients, two multicenter placebo controlled
trials with IL-2 were initiated. In both the SILCAAT and
the ESPRIT trial, “induction” and “maintenance” cycles
of sc IL-2 were added to virus-suppressive HAART. In
both trials a positive effect on peripheral CD4 T counts
was confirmed (temporary in ESPRIT and sustained in
SILCAAT). VL was continuously suppressed (by
HAART), but the occurrence of opportunistic infections
or death was not altered as compared to HAART only
[38]. Two smaller ANRS (Agence de Recherche sur le
SIDA) studies addressed additional questions. ANRS 119
showed that intermittent IL-2 therapy in HAART-naïve
patients with CD4 T counts between 300–500 cells/mm3
could induce a significant and sustained increase in CD4
T cells, though unfortunately without affecting VL, but,
based on CD4 T criteria, initiation of HAART could be
deferred [39]. The ANRS-NIH ILIADE trial suggested
that administration of 3 cycles of IL-2 in HIV-infected
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on HAART, could allow a significant delay in HAART
resumption following treatment interruption [40]. Taken
together, the potential beneficial effects of systemic IL-2
are rather limited; additionally, it is not devoid of side
effects, and sc administration is cumbersome. Therefore,
adjunctive systemic IL-2 therapy has not been adopted
in routine clinical care. This negative appreciation, how-
ever, does not preclude a local targeted IL-2 administra-
tion in conjunction with therapeutic vaccination.
Therapeutic use of interleukin 7 A single injection of
IL-7 in untreated HIV-infected subjects increased the
number of circulating CD4 and CD8 T cells, mainly
those of the central-memory type, without affecting the
frequency of Tregs, but with a slight increase of viral
RNA (blip) in half of the patients [41,42]. A prospective
open label trial (EudraCT) investigated the effect of
repeated sc IL-7 administration in those patients who
remained lymphopenic under fully virus-suppressive
HAART. A significant expansion of circulating memory,
but also naive, CD4 and CD8 T cells was observed, with-
out tolerability problems and without increases in T cell
activation or proviral load. Moreover, IL-7 treatment
counteracted IFN-α therapy-induced lymphopenia and
stimulated SIV-specific cytotoxic T lymphocyte
responses in SIV-infected rhesus macaques [43]. On-
going phase 3 trials should indicate whether IL-7 has a
role in correcting lymphopenia in patients who fail to re-
cover CD4 T cell counts under HAART (or in purging
the viral reservoir, as discussed above).
Therapeutic use of interleukin 15 Interleukin-15 has
several theoretical advantages over IL-2, in that it inhi-
bits apoptosis and enhances expansion of both CD4 and
CD8 memory T cells, as well as NK cells [67]. However,
systemic IL-15 administration in chronically SIV infected
macaques treated with HAART resulted in a delay in
viral suppression; and, when HAART was interrupted,
IL-15 co-treated animals experienced a more rapid loss
of CD4 T cells as compared to HAART-only treated ani-
mals [44]. These negative results have discouraged fur-
ther systemic administration, though IL-15 might still be
useful in conjunction with a HIV vaccine [68].
Therapeutic use of interleukin 21 Interleukin-21
might be the most suitable γ-chain cytokine for immu-
notherapeutic purposes. IL-21 by itself induced potent
antiviral activity in human CD8 T cells [69] and augmen-
ted the lytic potential of NK and CD8 T cells from HIV-
infected subjects [70-72]. HIV-1 specific IL-21 producing
CD4 T cell responses also contributed to durable viral
control through the modulation of HIV-specific CD8 T
cell function [73]. The in vivo relevance of all thesein vitro/ex vivo observations was most recently con-
firmed in a small trial of systemic IL-21 administration
in chronically untreated SIV infected rhesus macaques.
IL-21 administration was well tolerated, augmented the
cytotoxic potential of both T cells and NK cells, and pro-
moted B cell differentiation with increased SIV antibody
production, without an increase in cellular activation or
plasma VL [45]. These results encourage further testing
of IL-21 in conjunction with HAART and/or a specific
therapeutic vaccine.
Blocking negative regulatory receptors In an elegant
in vitro study, Shankar et al. recently showed that co-
culture of HIV-infected DC with naïve T cells induced
elevated membrane expression of a broad array of nega-
tive costimulatory molecules such as PD-1 and CTLA-4,
with a concomitant decreased expression of the effector
cytokines [74]. Many of these characteristics of T cell an-
ergy and exhaustion have also been described in T cells
from HIV-infected subjects.
High levels of PD-1 were shown on both CD4 and
CD8 T cells but particularly on HIV-1 specific cytolytic
T cells (CTL), and were correlated with CTL dysfunction
and apoptosis. PD-1 expression correlated directly with
VL and disease progression and inversely with CD4 T
counts. The natural ligand PD-L1 was significantly upre-
gulated on antigen-presenting cells (APC) from HIV-
infected individuals. Importantly, antibody-mediated
blocking of this interaction improved HIV-specific T cell
functions in vitro [75,76].
CTLA-4 is overexpressed on CD4 T but not on CD8
T cells and more particularly on HIV-specific T cells in
all infected subjects, except elite controllers. In vitro
blocking of CTLA-4 augmented HIV-specific CD4 T cell
proliferation. Additionally, CTLA-4 signaling resulted in
high CCR5 expression and enhanced susceptibility to
viral infection [75].
Contrasting effects of therapeutic blocking of PD-1
and CTLA-4 Administration of blocking antibodies to
PD-1 during chronic SIV infection in macaques had re-
markably positive effects. A rapid expansion of virus-
specific CD8 T cells with improved functional quality, as
well as B cell activation with increased SIV-specific anti-
bodies was observed. These immune phenomena were
associated with significantly reduced plasma VL and pro-
longed survival [46]. Interestingly, PD1 blocking actually
reduced immune hyper-activation, expression of type 1
IFN stimulated genes (ISG) and bacterial translocation,
and enhanced immunity to gut-associated pathogens
[77].
The results of CTLA-4 blocking in this primate model
were unfortunately less encouraging. Whereas an in-
crease in CD4 and CD8 T responses and a decrease of
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[47], the second trial showed no expansion of SIV-
specific CTL, but an increased activation of CD4 T cells
and viral replication at mucosal sites [48]. These discrep-
ant results may point to the delicate balance of enhan-
cing beneficial HIV-specific responses and increasing
deleterious immune activation.
Clearly, blocking various individual and combined
negative receptors should be studied in more detail in
SIV-infected animals; additionally, the potential synergy
of receptor blocking with therapeutic vaccines and other
anti-retroviral therapies should be investigated.
HIV-antigen specific immune therapies
A general overview is presented in Figure 1 and Table 2.
RemuneW
RemuneW was derived from a Congolese clade A/G
HIV-1, which was gp120 depleted, chemically inacti-
vated, irradiated, and emulsified with incomplete
Freund's adjuvant [112]. The first uncontrolled clinical
trials all showed that RemuneW induced HIV-specific T
cell responses [78]. In an open RemuneW trial in chron-
ically infected subjects, with suboptimal drug treatment,
a significant delay in viral rebound after treatment inter-
ruption (TI) was observed [78]. Another open trial inFigure 1 Schematic overview of HIV-antigen specific therapeutic vaccasymptomatic non-treated HIV-infected individuals
reported higher CD4 and CD8 T-cell counts and stable
VL [79]. However, these beneficial effects were not
observed in a randomized, double-blind, placebo-
controlled study with patients, receiving full HAART
during acute infection and vaccinated with either pla-
cebo, ALVAC (canarypox expressing env, gag, pol and
nef - see below) or with ALVAC+RemuneW. After ana-
lytical treatment interruption (ATI), there was no differ-
ence in viral rebound between the three arms [80].
Plasmid DNA vaccination
DNA-based vaccines have the conceptual advantage over
other vaccines in that they can express both viral anti-
gens and “molecular adjuvants”, such as cytokines or
costimulatory molecules. Moreover, they can be admi-
nistered repeatedly without inducing anti-vector immun-
ity. DNA vaccines have successfully been used
prophylactically in various infectious models in rodents,
but they are less efficient in primates. Nevertheless,
repeated intramuscular (im) immunization with carefully
designed optimized SIVmac239 gag and env plasmids by
Pavlakis’ group resulted in strong cellular and humoral
responses in naïve Indian rhesus macaques and a signifi-
cant sustained reduction of VL upon mucosal infection
with the related SIVmac251 [81]. This DNA vaccine wasination strategies.
Table 2 HIV-antigen specific therapeutic vaccinations
a) Non dendritic cell-based
Name Trial Species Baseline patients
characteristics







Human Therapy naïve RemuneW iv 2527 Increased HIV-specific T cell responses.




Human Therapy naïve RemuneW iv every 12 weeks for
132 weeks
223 Increasing CD4 and CD8 T cell counts





Human HAART ALVAC, ALVAC+ Remune,
placebo
iv injections Alvac @w 8,
12, 16, 20. Remune@w
0, 4, 12, 20
79 Safe and immunogenic. No difference
between the three groups after STI
on viral rebound.
[80]
Placebo controlled Indian rhesus
macaque
Chronic SIV HAART SIV mac239 gag and env
DNA vaccine
im 3 injections 23 Increase in HIV specific cellular





Chronic SIV HAART SIV mac239 gag and env
DNA vaccine + IL-15
In vivo electroporation 3 Sustained polyfunctional T cells.
One log decrease in VL.
[82]
Human HAART DNA vaccine consisting of
CTL epitopes
im injections w 0, 4, 8, 16 41 Safe and tolerable. In some persons
weak responses. Overall no differences
with placebo group.
[83]
VRC HIV DNA 009-00-VP
double blind placebo
controlled
Human HAART plasmid DNA encoding
subtype B Gag-Pol-Nef
and multiclade env
im injections w 0, 4, 8, 24 20 Poorly immunogenic. No effect on
viral rebound after ATI.
[84]
Human HAART Plasmid DNA multiclade Patch 12 Broader and higher HIV specific T-cell





Human ALVAC vCP1433 im injections w 0, 4, 8, 12 50 Safe and immunogenic. Delay in
treatment resumption of ATI.
[86]
ANRS 093 human HAART ALVAC+ lipo 6T 4 injections
followed by 3 cycles sc IL2
im injections of ALVAC w 0,
4, 8, 12. IL-2@w 16, 24, 32
71 Lower viral set point after ATI, correlated





Human HAART ALVAC ALVAC+ sc IL2 sc IL2
alone placebo
im injections of ALVAC w 0,
4, 8, 12. IL-2 sc for5 days in
8 week cycles
19 Lower viral rebound after ATI in ALVAC
vaccines. IL-2 + vaccine boosted CD4 T cell






ALVAC ALVAC+ Remune iv injection of ALVAC w8, 12,
16, 20. remune w 0, 4, 12, 20
79 No influence on VL after ATI. Increased




Human HAART ALVAC, ALVAC+ remune,
placebo
im injections of ALVAC w8,
12, 16, 20. Remune w0, 12,
20. ATI w24
52 No lower viral setpoint. Tendency
towards delay of rebound
[89]
ORVACS Human HAART ALVAC vcp1420 placebo im injections w 0, 4, 8, 20 65 Higher viral rebound in vaccines [90]
Human HAART Fowlpox gag/pol (PC) 3 im injections (w 0,4, 12).
ATI w20
35 Lower man viral rebound in FC group
and this is associated with IgG2 antibodies
to HIVp24
[91,92]
Fowlpox gag/pol IFN-y (FC
placebo

















Table 2 HIV-antigen specific therapeutic vaccinations (Continued)
Indian rhesus
macaque
im injections w10, 16.
STI w20
Tendency lower viral rebound after ATI
but not significant.
Rhesus macaque Chronic SIV HAART MVA+Ad5 gag and env im injection of Ad5/35
on day 74 and MVA-SIV
on day 134
Vaccinated animals had higher CD4 T cell
counts, SIV-specific cell-mediated immunity
and anti-SIV-neutralizing antibodies. After
ATI there was a sustained reduction in VL
and increased CD4 T cell responses.
[94]
Human HAART MVA nef sc injections w 0, 4, 16. ATI
w 18
14 Well tolerated. Induction HIV specific
responses. Lower viral rebound.
[95]
Human HAART MVA clade A p24/17 + CD8 T
cell epitopes
id 4 week interval 18 Amplification and broadening of CD8
and CD4 T cell responses. Induction of
CD8 T cell responses with capacity to




Chronic SIV HAART Ad5 and Ad35 SIV gag, env,
nef + IL15
im injections 15 Increased T cell responses no effect on
viral rebound.
[98]
w 16, 22, 36, 42
Human HAART rAd5 gag im injections 114 Safe and well tolerated. 0.5 log lower VL
16 weeks after A-STI
[99]
w 0, 4, 26.





Loading strategy Antigen Results References
Human 6 therapy-
naïeve
Pulsing Recombinant HIV-1 MN
gp160 or synthetic peptides
corresponding to HLA-A2-
restricted cytotoxic epitopes
of envelope, Gag, and Pol
proteins
Well tolerated and no effect on viral load. HIV specific responses were enhanced. [100]
Human 4 HAART Pulsing Seven CTL peptides with
HLA-A*2402 restriction
Well tolerated, discontinuation of HAART after vaccination failed to lower viral set
points. CD8 T cell responses induced in 2 out of 4 patients.
[101]
Pigtail macaque 36 HAART Pulsing of whole
blood
Gag proteins or peptides
spanning all 9 SIV proteins
SIV-specific CD4 and CD8T cell responses during antiretroviral cover and off treatment.




HAART Pulsing AT-2 inactivated virus Effective and durable SIV-specific cellular and humoral immunity is elicited. At week




Pulsing AT-2-inactivated virus Plasma viral load levels were decreased by 80% (median) over the first 112 days
following immunization. The suppression of viral load was positively correlated
with HIV-1-specific interleukin-2 or IFN-γ expressing CD4 T cells and with HIV-1
gag-specific perforin-expressing CD8 effector cells.
[104]
Human 12 HAART Pulsing Heat-inactivated virus Safe and well tolerated. Partial viral control 24 weeks after ATI . [105]
Human 24 therapy-
naïeve
Pulsing Heat-inactivated virus Feasible, safe and well tolerated. Modest decrease in viral load 24 weeks after first


















Table 2 HIV-antigen specific therapeutic vaccinations (Continued)
Human 29 HAART Live virus ALVACvcp1452 Viral load rebounded in both groups no differences in HIV-specific immune responses. [107]
ALVACvcp1452+ KLH
KLH
Human 9 HAART Electroporation Autologous mRNA encoding
Gag, Vpr, Rev and Nef
Mild adverse events. Full or partial HIV-specific immune responses in 7/9 subjects. [108]
Human 9 HAART Electroporation Autologous mRNA encoding
Gag, Vpr, Rev and Nef
Partial viral control . [109]
Human 17 HAART Electroporation mRNA encoding tat rev nef Vaccine was safe, 69 weeks after STI 6/17 patients remains off therapy. [110]
Human 6 HAART Electroporation mRNA encoding gag and
mRNA encoding tat rev nef
Vaccine was safe. HIV-specific responses against Gag were broader, higher and


















Vanham and Van Gulck Retrovirology 2012, 9:72 Page 11 of 21
http://www.retrovirology.com/content/9/1/72further improved by adding a plasmid encoding Nef-Tat-
Vif (NTV) fusion protein and applying in vivo electro-
poration [82].
The same group of researchers next used this strategy
in a therapeutic setting, comparing HAART alone or
HAART+3 DNA vaccinations in chronically SIV-infected
animals. A significant increase in cellular responses was
noted in the vaccinated animals. Upon ATI, the HAART-
only treated animals showed a full-blown viral rebound
and gradually progressed to AIDS, whereas only a limited
viral rebound was observed in the vaccinated animals and
a 10 times lower VL was sustained for 3 years [113]. At
that time, the combination of HAART and therapeutic
DNA vaccine was repeated in some of the originally vacci-
nated animals, using an improved strategy with a DNA
construct, containing the 5 SIV genes + IL-15+ IL-15 re-
ceptor α genes, and using in vivo electroporation. This
repeated vaccination resulted in sustained polyfunctional
central memory and effector memory CD4 and CD8 T
cell responses and, importantly, an additional 1 log reduc-
tion in VL load after ATI [114]. These studies therefore
provide proof-of-principle for plasmid DNA as a thera-
peutic vaccine.
However, in HAART-treated HIV-infected subjects the
evidence for success of DNA vaccination has not yet
been delivered. Repeated im injections of a DNA vac-
cine, based on CTL epitopes from multiple HIV-1 gene
products elicited only weak T cell responses in HAART
treated chronic patients [83]. The VRC-HIVDNA 009-
00-VP, consisting of 4 plasmids encoding a subtype B
Gag-Pol-Nef fusion protein and modified multiclade en-
velope constructs, was tested in a double blind placebo
controlled study on patients treated with HAART during
the acute/early phase. Even four im injections remained
poorly immunogenic, and there was no effect on viral
rebound after ATI [84]. A similar study in chronically
treated patients, using DNA plasmids containing genes
of several HIV-1 subtypes, apparently resulted in
broader and higher HIV-specific T cell responses, but
again there was no favorable effect on the viral rebound
after ATI [85]. The DermaVir concept, recently reviewed
by Lori, features a single plasmid DNA expressing 15
HIV antigens, a nano-particular formulation and a
dendritic cell (DC) targeting topical (skin patch) ad-
ministration. An impressive amount of safety and im-
munogenicity studies has been accumulated, but no
statistically convincing data on VL reduction have
been presented yet [115,116].
In a preventive setting, co-delivery of the genetic infor-
mation to produce IFN-γ, IL-12, IL-15 or IL-18 has been
shown to enhance T cell responses to SIV or HIV DNA
constructs in non-infected macaques [117]. A favorable
immune enhancement effect of co-delivered IL-12 or IL-
15 genetic information was confirmed in a therapeuticsetting in SIV-infected macaques [118] as well as in
HIV-infected chimpanzees [119]. A strong synergistic ef-
fect between IL-12 and in vivo electroporation was also
observed in preventive DNA vaccination in macaques
[120]. In a human preventive setting, however, co-
administration of IL-12 and/or IL-15 plasmids im failed
to enhance T cell responses to HIV-1 gag DNA vaccine
[121]. In vivo electroporation might be a viable option in
humans, as two recent studies in healthy volunteers con-
firm the afore mentioned macaque data in that the T cell
responses to intradermally (id) applied plasmid HIV
DNA, followed by in vivo electroporation, are much
stronger and more polyfunctional than those induced by
regular im injection without electroporation [122,123].
Viral vectors expressing HIV antigens
Canarypox vector (ALVAC) ALVAC is a recombinant
canarypox vaccine, expressing full length env and gag as
well as portions of pol and nef. The vCP1521 variant,
expressing subtype E gp120 and gp41, gag and protease
of subtype B, was used as a prime for AIDSVAX (Vax-
Gen bivalent gp120 subtype B/E), the recombinant
glycoprotein boost in the prophylactic RV144 “Thai”
trial, which showed a 31.2% protective efficacy against
HIV acquisition [124]. The mechanisms of this protec-
tion are still under active investigation.
ALVAC vCP1433 and vCP1452, based on subtype B
LAI sequences have been used in several therapeutic set-
tings with varying success. The open-label single arm
ANRS 094 study used 4 monthly im ALVAC injections,
showing safety and immunogenicity [86]. The ANRS 093
trial used 4 im injections of ALVAC and Lipo-6T, a mix-
ture of HIV derived lipopeptides, followed by 3 sc cycles
of IL-2 in chronic HIV patients under stable HAART
and included a control group under HAART alone. After
ATI, a larger proportion of subjects in the vaccine group
managed to lower their viral setpoint (24% vs 5%), and
this was correlated with an enhanced vaccine-induced
CD4 T cell response [87]. A follow-up study in HAART
patients (ACTG A5024) included 4 arms, comparing
placebo with ALVAC-HIV alone, sc IL-2 +ALVAC pla-
cebo, and the combination ALVAC-HIV and IL-2. Viral
rebound, assessed 12 weeks after ATI, was 0.5 logs lower
in both ALVAC-HIV vaccinated groups, whereas IL-2
increased CD4 T counts but did not diminish VL [88].
These early studies suggest that ALVAC vaccination can
partly prevent viral rebound in chronically infected
HAART patients.
As mentioned, a double blind placebo controlled trial
with ALVAC-HIV or ALVAC-HIV and RemuneW in
patients already treated in the acute phase (QUEST),
confirmed induction of immune responses, but did not
result in better virological control 24 weeks after
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chronic patients (CTN173) confirmed that both vaccines
were unable to lower the viral setpoint, but nevertheless
tended to delay rebound and extend time to restart
HAART, which was also marginally correlated with
higher IFN-γ and IL-2 responses [89].
Finally, a rather disappointing result was obtained in the
ORVACS study, where 4 and 3 injections of ALVAC
vCP1452 were compared with placebo in chronic HAART
patients. The vaccines were immunogenic, but both vacci-
nated groups showed a higher viral rebound and had to
resume treatment more rapidly than the placebo group
[90]. A lower CD4 nadir and a higher vaccine-induced
HIV-specific CD4 T cell cytokine response in Enzyme
Linked Immunosorbent Spot Assay (ELISPOT) were pre-
dictive of this adverse outcome [125]. This result is some-
how reminiscent of the prophylactic STEP trail, where
vaccine-induced CD4 T cell activation has been invoked to
explain apparently enhanced susceptibility to HIV infec-
tion [126].
Clearly, these various ALVAC trials provided rather
contradictory results. Nevertheless, they indicate that
baseline characteristics of patients (e.g. pre-treatment
VL or CD4 T cell nadir) need to be carefully matched,
and they confirm the notion that vaccine-induced im-
mune activation can have both beneficial and adverse
effects: whereas HIV-specific T cell activation is required
to control viral rebound, immune stimulation can also
increase the susceptibility of CD4+ target cells to pro-
ductive infection.
Fowl pox An Australian group compared two recom-
binant fowl pox vectors: one expressing gag/pol from
subtype B only (a so-called partial construct or PC),
while the second co-expressed human IFN-γ (full con-
struct or FC), in addition to a placebo (diluent only).
Thirty five fully HAART-treated subjects were rando-
mized to the 3 regimens (12 placebo −11 PC −12 FC)
and received 3 im injections (week 0, 4 and 12), and
were then followed up for 52 weeks under HAART [91].
A subset (7 placebo; 8 PC and 10 FC subjected) under-
went ATI for 20 weeks thereafter [92]. The most re-
markable observation was a significantly lower mean
viral rebound in the FC patients (+ 0.96 log), as com-
pared to placebo (+ 1.80 log) and PC (+ 1.78 log). The T
cell responses during the vaccination period were very
weak. During ATI the IFN-γ ELISPOT increased in all
three groups, but the changes were higher in the placebo
as compared to the vaccinated patients. In a post hoc
analysis, however, it was found that IgG2 antibodies to
HIV p24 were present at 52 weeks (time of ATI start) in
5/9 FC patients and not in the PC or placebo patients.
The presence of these antibodies was associated with
lower viral rebound [127]. Clearly, the addition of IFN-γto the vaccine seemed to be beneficial, and IgG2 anti-
bodies were implicated in this protective effect.
Modified Vaccinia Ankara (MVA) Several constructs
expressing various HIV or SIV genes in replication-
deficient poxvirus have been used as prophylactic vac-
cines in macaques, preceded by plasmid DNA priming
with the same antigens. Partial, but sustained, protection
has repeatedly been shown against homologous chal-
lenges: in most cases infection could not be prevented,
but VL was lower and disease progression delayed or
halted [128-130]. Whereas correlations with neutralizing
antibodies as well as CD4 and CD8 T cell responses
were noted in some cases, a crucial role for CD8 T cells
in this protection was strongly suggested by a CD8 de-
pletion approach in the study of Amara [131].
A few studies addressed the potential therapeutic ef-
fect of MVA expressing SIV antigens in infected maca-
ques under antiretroviral treatment. A small trial using
MVA gag-pol/MVA env or MVA tat-ref-nef in SIV-
infected animals, treated with the NRTI PMPA, showed
a tendency towards lower viral rebound after ATI in the
vaccinated groups [93]. A regimen with combined
Adenovirus constructs (see below) and MVA expressing
gag and env in infected and treated macaques provided a
more sustained reduction in VL and increase of CD4 T
cell counts, correlated with increased anti-SIV cell-
mediated and humoral responses [94].
In HIV-infected subjects under HAART, nef-expres-
sing MVA was shown to induce CD8 and CD4 T cell
responses in some patients and there was a relatively
lower viral rebound after treatment interruption [95].
An elegant series of studies was carried out in 16 chron-
ically infected patients under HAART, using an MVA
construct expressing consensus clade A p24/p17 and
multiple CD8 T cell epitopes. The authors showed that
both CD4 and CD8 T cell responses were amplified and
broadened, and that CD8 T cells acquired the capacity
to inhibit HIV-1 replication in vitro [96,97]. Especially
the latter characteristic seems most important for poten-
tial therapeutic effect.
Other groups have also developed promising HIV
MVA constructs that elicited polyfunctional CD4 and
CD8 T cell responses in either healthy or HIV infected
subjects [132-134], and more formal testing in thera-
peutic trials is presumably ongoing.
Adenovirus constructs Two phase IIb studies, STEP
and Phambili, evaluated the prophylactic effect of the
replication- defective recombinant adenovirus type 5
(rAd5) MRK gag/pol/nef vaccines in healthy volunteers.
Clearly, neither trial showed a decrease in HIV acquisi-
tion, nor decreased early plasma VL in vaccinees, who
were infected. A post-hoc analysis showed even an
Vanham and Van Gulck Retrovirology 2012, 9:72 Page 13 of 21
http://www.retrovirology.com/content/9/1/72increased risk of infection in uncircumcised vaccinated
men, who were already Ad5 seropositive before vaccin-
ation [135]. This deleterious effect was tentatively
explained by the observation that Ad5 could induce ex-
pansion of memory CD4 T cells with a mucosal homing
phenotype, which are readily susceptible to HIV-1. Sev-
eral studies provided evidence that the untoward effect
of pre-existing Adeno immunity by natural infection
could have a negative impact on immune responses
against HIV and could increase susceptibility towards
HIV infection, even if rare Adeno serotypes were being
used [126,136,137].
Human replication deficient rAd5 and rAd35 vectors,
encoding SIV gag, env and nef (with or without IL-15 en-
coding cassettes), were used in chronically SIVmac251
infected and properly treated macaques, followed by
ATI. HIV specific T cells were increased but viral re-
bound was not influenced [98].
The AIDS Clinical Trial Group (ACTG) protocol
A5197 was a randomized placebo controlled trial to test
rAd5 expressing gag in chronically infected patients
under stable HAART with 77 persons in the vaccinated
and 37 in the placebo group. Interestingly, 16 weeks
after ATI, the plasma VL was 0.5 logs lower in the vacci-
nated group [99].
Though the therapeutic trial in SIV-infected macaques
was not promising, the rather positive result of the ACTG
trial in chronic HAART patients raises some hope. There
are several recent studies in seronegative controls indicat-
ing that a prime-boost regimen with HIV env and gag/pol
DNA/Ad5 may enhance antibody titers and T cell
responses. Importantly, the T cells showed not only
increased poly-functionality, but also a significant HIV-
suppressive effect towards several HIV strains, including
transmitted/founder viruses in vitro [138,139]. Another
possible way forward is the subsequent vaccination with
rAD5 and rMVA, with synergistic activities on effector
memory and central memory CD8 T cells [140].
Dendritic cell based immunotherapy
A number of DC-based therapeutic trials have recently
been completed in animals and humans. DC have the
capacity to process proteins through both MHC class I
and class II pathways for stimulation of CD8 or CD4 T
cells respectively. Antigen can be provided to DC in
many formats: as peptides, whole proteins or apoptotic
cells, and also in a “genetic” format by transfecting DC
with antigen-encoding viral vectors in DNA or mRNA
format.
a) Antigenic peptides and recombinant proteins
The use of antigenic peptides is an efficient loading
strategy, but DC can also be pulsed with
recombinant HIV proteins [24]. In principle,“exogenous” protein should preferentially induce
MHC (HLA)-class II restricted CD4 T cells, whereas
peptides could stimulate both CD4 and CD8 T cells,
according to their class I or II binding, depending on
their length and composition. The first small trial in
humans was performed by Kundu and showed that
the administration of HIV peptides or protein-pulsed
autologous DC was well-tolerated and could enhance
the immune response to HIV in therapy-naïve
patients with normal CD4 T cell counts [100]. In a
second trial, 6 doses of synthetic HIV-1 peptide-
pulsed autologous DC were administered to 4
HAART-treated, HLA-A2402 individuals who
underwent ATI: no significant changes in VL or CD4
T cells were observed during ATI [101]. Finally, De
Rose et al. performed an intriguing trial in pigtail
macaques, where blood was exposed ex vivo to
overlapping SIV peptides or medium for 1 hour and
re-injected. This procedure was repeated 7 times.
SIV specific CD4 and CD8 T cell responses were
induced; and, remarkably, virus levels were
approximately 10-fold lower for 1 year in immunized
animals as compared to medium controls [102]. A
basic problem with peptides and proteins, however,
is that it is difficult to cover HIV variability and HLA
polymorphisms at an affordable cost.
b)Whole inactivated virus
Whole inactivated HIV-1 particles have successfully
been used in DC vaccination of mice, monkeys and
humans. Two prophylactic trials were performed in
severe combined immunodeficient (SCID) mice,
reconstituted with human PBMC. Yoshida and
colleagues used IL-4 DC (i.e. monocytes
differentiated into DC in the presence of IL-4 and
GM-CSF and matured with IFN-α), whereas Lapenta
and colleagues used IFN-DC (i.e. monocytes
differentiated into DC in the presence of IFN-α and
IL-4). In both trials, autologous DC were pulsed with
aldrithiol (AT)-2-inactivated R5 subtype B viruses:
HIV-1SF-162 by Lapenta [141] and HIV-1JR-CSF by
Yoshida [142]. After vaccination with the pulsed DC,
HIV-1 specific CD4 and CD8 T cells were generated
in vivo. Moreover, upon infection with homologous
virus, there was also evidence for partial protection.
Around the same time, Lu et al. published their
paper on therapeutic vaccination in Chinese rhesus
macaques [103]. They used AT-2-inactivated
SIVmac251-pulsed IL-4 DC, matured with the
classical “Jonuleit” cytokine cocktail, consisting of IL-
1β, tumor necrosis factor-α, IL-6 and Prostaglandin
E2 [143]. All animals displayed a significant decrease
in viral load 10 days after vaccination and an
increased CD4 T cell count. Clearly enhanced SIV-
specific cellular immunity was also observed.
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chronically HIV-infected patients, using IL-4 DC
pulsed with autologous AT-2-inactivated virus. This
resulted in an effective HIV-1-specific T cell response
with sustained viral suppression of over 90% in 8 of
18 subjects [104]. Based on statistical correlations,
robust virus-specific CD4 T helper cells were
required to induce and maintain virus-specific CD8
T effector cells for virus containment.
In another clinical trial, Garcia used heat-inactivated
autologous virus to pulse IL-4 DC: in 12 HIV-1-
infected persons under HAART, partial viral control
could be achieved 24 weeks after ATI [105]. In
contrast to the observations of Lu et al., the HIV-
specific cellular immune response was weak and
transient in Garcia’s study. The latter author also
performed a double blind clinical trial on untreated
HIV-1 infected patients with IL4 DC pulsed with
heat-inactivated virus [106]. VL in the active group
was maintained at a lower level as compared to the
placebo group at week 48. However, this result was
inversely correlated with HIV-1 specific immune
responses.
Clearly, although Lu’s and Garcia’s vaccination
strategies both yielded a positive effect on VL, the
association between VL and T cell responses was
different. Whether this discrepancy is due to the
different inactivation procedure (AT2 vs. heat
inactivation) or other factors remains to be
investigated.
Unfortunately, DC loading with inactivated virus is
difficult to standardize due to numerous variables:
type and activation state of infected cells, method of
virus inactivation, and the amount of antigen in the
preparation. Moreover, it requires meticulous quality
control testing on the inactivation procedure in
order to eliminate any biological risk of infection.
c) Live viral vectors
As already discussed, direct vaccination with
Canarypox virus vectors carrying HIV-1 genes
(ALVAC) yielded discordant results in several
studies. Recently a phase I/II clinical trial was
performed, comparing direct injection of ALVAC
vCP1452 and keyhole limpet hemocyanin (KLH) as
adjuvant with injection of autologous IL-4 DC
infected ex vivo with ALVAC vCP1452 and treated
with KLH. After three injections, subjects underwent
a minimum of a 12-week ATI. Viral load rebounded
in both groups and there was also no difference in
HIV specific responses [107].
d)mRNA and DNA
Loading HIV antigens encoded by nucleic acid, either
cDNA or mRNA, is easier to standardize, it does not
carry infectious risk, and hence seemsstraightforward for clinical applications. In our
hands, transfection of IL-4 DC with cDNA is less
attractive than mRNA, as cDNA electroporation
resulted in more cell death and expression levels
were lower, probably due to the more stringent
transformation conditions required to penetrate into
the nucleus. Transfection with mRNA encoding
antigens requires cytoplasmic penetration only and
was very efficient for loading DC and subsequent
stimulation of HIV-specific T-cells [144].
Several clinical trials have already been performed
based on DC electroporated with mRNA encoding
HIV-1 proteins. In AGS-004, nine HAART-treated
individuals were vaccinated with autologous IL-4 DC
electroporated with mRNA encoding CD40L and
autologous HIV antigens Gag, Vpr, Rev and Nef.
Patients received monthly injections in combination
with HAART [108]. Seven out of nine patients
showed proliferative CD8 T cell responses. This
vaccine was further evaluated in a phase II study,
resulting in partial viral control [109]. Another
recent clinical trial was performed by Allard et al. In
this study, 17 HIV infected individuals on HAART
received 4 vaccinations with 4 week intervals of
autologous IL-4 DC electroporated with mRNA
encoding a subtype B TatRevNef fusion protein. Four
weeks after the last vaccination, treatment was
interrupted [110]. Six out of 17 patients remained off
therapy 69 weeks after ATI. However this clinical
result was not better than a historic control group
undergoing STI, despite the induction and
enhancement of CD4 and CD8 T cell responses
specific for the vaccine [110]. Around the same time
our group also performed a phase I/II clinical trial: 6
HIV-infected individuals who received stable
HAART were included. Individuals were vaccinated
with autologous IL-4 DC electroporated with mRNA
encoding the same TatRevNef fusion protein as in
Allard’s study and with IL-4 DC expressing subtype
B Gag mRNA. After vaccination, HIV-specific
responses to Gag were increased in magnitude,
breadth and proliferative capacity. Although no
virological parameters could be measured because
patients did not undergo ATI, we showed that the
CD8 T cells from the vaccines could inhibit
superinfection of autologous CD4 T cells with
vaccine related IIIB virus in vitro [111].
Overall, 210 patients (60 therapy naïve and 150 on
HAART) have been recruited in clinical trials with
DC based vaccines. The safety profile has been
excellent and DC therapy clearly elicits HIV-1
specific immunological responses, but only four of
these studies reported virological responses to
immunization [145].
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Current immunotherapeutic strategies involve the
ex vivo manipulation of autologous DC. This
vaccination procedure is labor-intensive, logistically
complicated, expensive and not useful in developing
countries. A possible solution is direct in vivo
delivery of suitable antigens and co-stimuli to
resident DC. A first attempt in animal models was to
apply protein antigens in complex with antibodies to
DC-specific membrane molecules such as DC-SIGN
or DEC-205 [146,147]. A future strategy could be the
delivery of biodegradable nanoparticles, which will be
taken up by endocytic DC in vivo, such as the
DermaVir patches [115].
Conclusions
Early attempts of immunotherapy, during the pre-
HAART era, included non-specific (e.g. IFN and IL-2)
and HIV-specific (e.g. Remune) immune interventions in
patients who were either untreated or received mono- or
dual drug therapy. In some cases positive effects have
been reported, but these trials were small and usually
not well controlled. During the last 10–15 years, the
concept of immunotherapy as a supplement to full
HAART has been further developed, with the ultimate
aim to reduce or even replace drug therapy.
Amongst the non-antigen-specific immune approaches,
systemic IL-2 has been exhaustively investigated and was
ultimately shown not to provide clinical benefit in
addition to HAART. It remains to be seen whether sys-
temic use of other common γ chain cytokines, such as
IL-7 or IL-21, could be useful for particular indications
(e.g. to counteract lymphopenia). The newer “non-
specific” approach is to block negative regulatory path-
ways, such as PD-1 or CTLA-4 signaling, both over-
expressed during HIV infection. Experimental treatment
in SIV-infected macaques indicated that PD-1 blocking
helped to control viremia and to reduce immune activa-
tion. In contrast, CTLA-4 blocking resulted in increased
viremia, most probably as a result of an unfavorable bal-
ance between too much non-specific and insufficient spe-
cific immune activation.
The obvious goal of therapeutic vaccination is to
stimulate effective HIV-specific T cell responses, primarily
cytolytic/virus suppressive CD8 T cells with supporting
CD4 T cell help, while avoiding increased HIV-
susceptibility of target cells. To that end, protein or particu-
late antigen is conceptually not the best option, since it
primarily results in CD4 T and B cell activation: antibodies
are considered ineffective and CD8 T cells seem essential in
immune protection post infection.
Repeated im vaccination with plasmid DNA encoding
various HIV antigens, along with cytokines, was success-
ful in lowering VL in macaques, but this has not yetbeen confirmed in humans, despite repeated attempts.
However, the immunogenicity of DNA vaccination is
being improved by innovative constructs and enhanced
delivery systems [148]. Especially for applications in less
sophisticated environments, DNA vaccines have the ad-
vantage of being stable and to carrying no infectious
risk, but because they are considered “genetic therapy”,
the development of DNA vaccines is subjected to strict
regulations [149].
Recombinant viral vectors have been applied rather ex-
tensively in therapeutic vaccination trials. In most cases
poxviruses (e.g. canary pox, fowl pox and MVA) and oc-
casionally Adenoviruses were used. A fair number of en-
couraging results were observed in infected/treated
macaques and patients in terms of T cell responses, and
in some cases also VL reduction after ATI was observed.
However, the variable results, obtained with the most ex-
tensively used canarypox platform, ALVAC, illustrate
that apparently similar trials can have quite discrepant
outcomes. Again, this may be the result of a delicate bal-
ance between the beneficial enhancement of anti-HIV
CD8 T cell immunity and the deleterious effect of non-
specific immune activation, inducing increased cellular
susceptibility to HIV infection.
DC-based therapy has been developed in a therapeutic
context, with various antigenic formats and correspond-
ing loading strategies. Remarkably positive results in
terms of viral control have been obtained with au-
tologous inactivated virus loaded DC. DC trials with
safer and less cumbersome formats (e.g. RNA) are
ongoing, but the first results suggest that there is a
need for improvement and further simplification of
this methodology.
Collectively, it seems that HIV immunotherapy, al-
though still highly experimental, is a viable option to ex-
plore. Although some beneficial effects have been
described in untreated individuals, most evidence today
argues that more effective immune responses can be
induced under HAART coverage. In most trials, poten-
tially favorable T cell responses were induced, while
effects on VL have at best been transient. This limited
success should not come as a surprise, since in most
cases antigens from one particular or a limited number
of HIV strains were used as immunogen and even in
those trials, where the “autologous” virus or sequences
thereof were used, epitopes from which the immune sys-
tem had already escaped may have been presented.
To overcome these restrictions, new options are avail-
able. One is to immunize with a set of the most con-
served, subdominant epitopes, mainly in the structural
core genes (i.e. Gag) in order to focus and “teach” T cells
to effectively react against at least some determinants
which the virus cannot possibly escape from without
completely losing infectivity. Obviously, this strategy
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large numbers of different stretches of antigens, in view
of the requirement to accommodate the HLA restric-
tions and to allow T cell receptor “maturation” by
gradual somatic mutations. One such approach was pro-
posed by Letourneau et al. [150]. With these antigens,
strong immune responses were already induced both in
mice and macaques, using HIV conserved alphavirus
replicon DNA and electroporation [151]. A similar ap-
proach, focusing on different epitopes was proposed
more recently by C. Brander [152]. A second alternative
is the so-called mosaic gag approach, where a large num-
ber of natural HIV sequences are included by in silico re-
combination (ftp://ftp-t10.lanl.gov/pub/btk/mozaïek) for
maximum coverage of potential T cell epitopes of HIV-1
group M, including potential escape variations [153,154].
This approach has successfully been applied in maca-
ques, using DNA+recombinant vaccinia boost [155-157].
Interestingly, this viral construct also induced broad
responses in PBMC from HIV-1 B or C infected subjects
[157].
The next important question to address is how to de-
liver this improved antigen in vivo. Clearly, genetic con-
structs, either plasmid DNA, mRNA or recombinant
viruses are suitable. All three formats have advantages
and drawbacks as explained. Our own preference goes
to mRNA, as it is flexible and clean, can include a large
number of antigens and variants, and does not carry any
infection or insertional risk or risk for vector-related ad-
verse immune reactions [25]. This safety advantage of
mRNA-based vaccines as compared to plasmid DNA or
viral vectors is reflected in their classification by the au-
thorities (FDA in the USA and Paul Ehrlich Institute in
Germany) as no gene therapy approaches. This relaxes
the requirements concerning preclinical toxicology stud-
ies in animals [149].
Another feature of mRNA is, however, its biological
instability (sensitivity to ubiquitous RNAses); and there-
fore it has mostly been used to load patient-derived DC
ex vivo, a strategy which is not applicable at a larger
scale. Recent evidence, however, indicates that mRNA
can be chemically stabilized to be injected as “naked”
RNA in vivo (e.g. intranodally) and/or formulated with
either cationic lipids or positively charged proteins. The
latter technologies have been refined over the years, and
are now ready for clinical application [158-160].
In addition to the antigen and its format or formula-
tion, further signals may be required to optimize the im-
mune responses. Especially if the format is DNA or
RNA, a clearly defined genetic adjuvant is most attract-
ive, as it will restrict the costimulatory effect to the site
where the immune response is elicited. Th1-skewing (IL-
12, IFN-γ), common γ chain or cytokines, TNF ligand
members or Toll-like receptor ligands have been used withsome success [28]. From our review two new candidates
emerge: IL-21 [45] and PD-1 blocking agents [161].
The desired clinical outcome of a therapeutic vaccine
is to keep the VL under control and restore CD4 T cell
counts through CD8 T cell-mediated suppression of viral
re-emergence. However, there are no easy correlates for
this protective effect while the patient is still on
HAART. A straightforward ELISPOT using a standard
subtype B set of peptides provides a first indication of
immunogenicity, but it does not represent a true correl-
ate for protection. Expanding the breadth of the T cell
responses by testing many peptide variants, “potential T
cell epitopes” (PTE) [162], increasing avidity by testing
low peptide concentrations or improving the “quality” in
terms of lytic capacity of CD8 T cells or poly-functionality
as well as expansion of HIV-specific effector-memory or
central memory CD4 and CD8 T cells have all been pro-
posed as useful [6,8], but these tests remain somewhat in-
direct correlates and require rather delicate and
cumbersome experimental approaches. As mentioned,
several authors, including ourselves, have proposed to
measure the vaccine-induced capacity of the patients’
CD8 T cells to suppress various HIV isolates in vitro, as
this function has repeatedly been associated with the
“elite controller” status [18-20,111]. Obviously, this type
of functional test is also difficult to standardize, but it has
the conceptual advantage of being a direct correlate of
the desired protective effect.
Another important parameter to consider is whether
immunotherapy or any other intervention aiming at a
“functional cure” could reduce the size of the latent res-
ervoir. Several assays have been proposed to measure re-
sidual replication-competent virus in purified CD4 T
cells, based on (enhanced) viral culture as well as on an
array of PCR-based methods quantifying intracellular
viral mRNA (unspliced or multiple spliced) or proviral
DNA. With regard to the latter, it is important to deter-
mine integrated versus non-integrated proviral DNA as
well as the precise cell subset of the reservoir (activated
versus resting T cells, central-memory versus terminally
differentiated, macrophages, dendritic cells etc.). More-
over, the measurement should not be limited to blood,
but also consider reservoirs in lymphoid tissues (periph-
eral or gastro-intestinal-associated lymph nodes) as well
as “sanctuary sites” (such as the CNS or the genital
tract). While the conceptual importance of these mea-
surements is evident, these assays are presently not stan-
dardized and it remains to be determined which ones
are most predictive of what we really want to know: will
our intervention be able to mitigate or abrogate viral re-
bound after subsequent interruption of HAART [1,30]?
Since there is no definite ex vivo/in vitro correlate of
protection and since the SIV macaque model does not
necessarily predict effects in human trials, one needs to
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ruption to assess the ultimate clinical effect. In view of
the observed variability in trial outcome, there is a clear
requirement for a carefully matched and sufficiently
large placebo group. Treatment interruption, even when
guided by CD4 T cell counts and carefully designed to
avoid emergence of drug resistance, is being considered
as harmful in the long run since the SMART trial [29].
To address this problem, Routy recently reanalyzed the
SMART data for the effects of a limited duration of
treatment interruption (e.g. 16 weeks) in patients on
stable HIV-suppressive HAART with CD4 T counts >
400/μL, a CD4 T cell nadir of > 200/μL and without con-
comitant diseases. He concluded that ATI under those
conditions is safe and thus acceptable in the context of a
well monitored therapeutic trial with timely resumption
of HAART in case of rebound and/or CD4 T cell drop
[163].
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